Sheikhah Alya, a Dubai-based crypto investor, has announced a significant change in her crypto portfolio, selling all of her XRP holdings to increase her exposureSheikhah Alya, a Dubai-based crypto investor, has announced a significant change in her crypto portfolio, selling all of her XRP holdings to increase her exposure

XRP Investor Dumps token for Shiba Inu (SHIB)

2026/02/10 09:00
3 min read

Sheikhah Alya, a Dubai-based crypto investor, has announced a significant change in her crypto portfolio, selling all of her XRP holdings to increase her exposure to Shiba Inu (SHIB).

The announcement comes amid a recovery in the crypto market following a sharp downturn earlier this month. While Alya did not provide proof of the transactions, her decision highlights a shift from a large-cap, utility-driven asset to a high-volatility meme coin.

Market Context and Recent Performance

The portfolio adjustment follows a steep market correction on February 5 that affected both XRP and SHIB. At the low point, XRP traded near $1.13, while SHIB fell to approximately $0.000005587. Since then, XRP has rebounded to $1.44, representing a recovery of more than 27%, whereas SHIB has climbed to $0.000006159, marking a 10% gain.

Despite the swift recovery, XRP is down by over 21% year-to-date, despite starting the year with a rally. SHIB remains down roughly 11% for the year. Alya’s decision appears timed with these fluctuations, potentially seeking short-term growth opportunities amid market volatility.

Strategic Implications of the Shift

By selling her XRP for SHIB, Alya is prioritizing a high-risk, high-reward approach over steady, fundamentals-based growth. XRP is recognized for its utility in cross-border payments and has achieved notable institutional adoption alongside growing regulatory clarity.

However, for SHIB, the focus is on community interaction, viral trends, and investor sentiment. Unlike XRP, SHIB does not concentrate on any technology or real-world fundamentals. This change emphasizes her preference for timing rapid price fluctuations compared to stability.

The announcement has elicited mixed responses within the crypto community. Some observers praised Alya’s decisive move, while many others questioned her decision. Critics called her decision the wrong choice, with some suggesting maintaining positions in both instead of selling XRP outright. Switching from SHIB to XRP might offer more sustainable growth, given XRP’s integration with financial infrastructure and broader market adoption.

Alya’s Bullish Stance on SHIB

Alya has consistently expressed optimism about Shiba Inu in recent weeks. In early January, she projected significant gains for SHIB in three to six weeks. Her decision to sell her XRP holdings in favor of SHIB suggests confidence in these predictions, anticipating that SHIB could outperform other market assets during the current recovery phase.

Despite the token’s past performance, some critics remain cautious, citing its enormous circulating supply of approximately 590 trillion coins as a limiting factor for major price advances. Other experts have recommended that investors sell major assets like Bitcoin in favour of XRP. Perspectives like these may cast Alya’s decision in a more critical light, particularly as the market navigates the coming weeks.

Disclaimer: This content is meant to inform and should not be considered financial advice. The views expressed in this article may include the author’s personal opinions and do not represent Times Tabloid’s opinion. Readers are urged to do in-depth research before making any investment decisions. Any action taken by the reader is strictly at their own risk. Times Tabloid is not responsible for any financial losses.


Follow us on Twitter, Facebook, Telegram, and Google News

The post XRP Investor Dumps token for Shiba Inu (SHIB) appeared first on Times Tabloid.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.423
$1.423$1.423
-1.59%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26